Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Thomas Yau,Vittorina Zagonel,Armando Santoro,Mirelis Acosta-Rivera,Su Pin Choo,Ana Matilla,Aiwu Ruth He,Antonio Cubillo Gracian,Anthony B El-Khoueiry,Bruno Sangro,Tarek E Eldawy,Jordi Bruix,Giovanni Luca Frassineti,Gina M Vaccaro,Marina Tschaika,Christian Scheffold, Petra Koopmans,Jaclyn Neely,Fabio Piscaglia

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 12|浏览32

暂无评分

摘要

Nivolumab plus cabozantinib with or without ipilimumab showed encouraging preliminary antitumor activity and had consistent safety profiles with those established for the individual drugs in patients with advanced hepatocellular carcinoma.

查看译文

关键词

advanced hepatocellular carcinoma,nivolumab,hepatocellular carcinoma,cabozantinib,ipilimumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要